Ya‐Wen Hung

443 total citations · 1 hit paper
10 papers, 314 citations indexed

About

Ya‐Wen Hung is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Ya‐Wen Hung has authored 10 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hepatology, 5 papers in Epidemiology and 3 papers in Molecular Biology. Recurrent topics in Ya‐Wen Hung's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Liver Disease Diagnosis and Treatment (4 papers) and Gut microbiota and health (3 papers). Ya‐Wen Hung is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Liver Disease Diagnosis and Treatment (4 papers) and Gut microbiota and health (3 papers). Ya‐Wen Hung collaborates with scholars based in Taiwan. Ya‐Wen Hung's co-authors include Yi‐Hsiang Huang, I‐Cheng Lee, Ming‐Chih Hou, Pei‐Chang Lee, Yu‐Lun Kuo, Jiing‐Chyuan Luo, Yee Chao, Rheun‐Chuan Lee, Ming‐Chih Hou and Chiang‐Shan R. Li and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Journal of Abnormal Psychology.

In The Last Decade

Ya‐Wen Hung

9 papers receiving 311 citations

Hit Papers

Gut microbiota and metabolites associate with outcomes of... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
    2022 132 citations Pei‐Chang Lee, Ya‐Wen Hung et al. Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ya‐Wen Hung Taiwan 7 153 118 100 88 40 10 314
Shana White United States 6 60 0.4× 102 0.9× 60 0.6× 51 0.6× 32 0.8× 9 267
George Kyriakopoulos Greece 12 76 0.5× 23 0.2× 65 0.7× 70 0.8× 22 0.6× 30 320
F. Chapel France 7 175 1.1× 30 0.3× 181 1.8× 37 0.4× 29 0.7× 15 326
Lina Jiang China 8 35 0.2× 29 0.2× 52 0.5× 63 0.7× 63 1.6× 15 271
Kana Kurokawa Japan 11 10 0.1× 87 0.7× 40 0.4× 52 0.6× 142 3.5× 23 292
Soichiro Kawata Japan 10 34 0.2× 145 1.2× 50 0.5× 24 0.3× 108 2.7× 26 279
David A. Klibansky United States 7 46 0.3× 212 1.8× 105 1.1× 23 0.3× 56 1.4× 12 327
Qiaofeng Zhong China 8 16 0.1× 89 0.8× 27 0.3× 43 0.5× 61 1.5× 20 230

Countries citing papers authored by Ya‐Wen Hung

Since Specialization
Citations

This map shows the geographic impact of Ya‐Wen Hung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ya‐Wen Hung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ya‐Wen Hung more than expected).

Fields of papers citing papers by Ya‐Wen Hung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ya‐Wen Hung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ya‐Wen Hung. The network helps show where Ya‐Wen Hung may publish in the future.

Co-authorship network of co-authors of Ya‐Wen Hung

This figure shows the co-authorship network connecting the top 25 collaborators of Ya‐Wen Hung. A scholar is included among the top collaborators of Ya‐Wen Hung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ya‐Wen Hung. Ya‐Wen Hung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
2.
Lee, Pei‐Chang, Yi‐Ping Hung, Ya‐Wen Hung, et al.. (2024). Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. Journal of Hepatology. 82(1). 51–61. 10 indexed citations
3.
Hung, Ya‐Wen, I‐Cheng Lee, Rheun‐Chuan Lee, et al.. (2023). Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 13(1). 29–40. 8 indexed citations
4.
Lee, Pei‐Chang, et al.. (2022). Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. Cancer Immunology Immunotherapy. 71(11). 2631–2643. 33 indexed citations
5.
Lee, Pei‐Chang, Ya‐Wen Hung, I‐Cheng Lee, et al.. (2022). Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 10(6). e004779–e004779. 132 indexed citations breakdown →
6.
Lee, I‐Cheng, Rheun‐Chuan Lee, Ya‐Wen Hung, et al.. (2021). Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. Cancers. 13(17). 4325–4325. 9 indexed citations
7.
Lee, Pei‐Chang, et al.. (2021). Association of gut microbiota and metabolites with tumor response to immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 39(15_suppl). e16165–e16165. 6 indexed citations
8.
Hung, Ya‐Wen, et al.. (2020). Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan.. Journal of Clinical Oncology. 38(15_suppl). e16627–e16627. 6 indexed citations
9.
Lee, I‐Cheng, Ya‐Wen Hung, Chien‐An Liu, et al.. (2019). A new ALBI‐based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver International. 39(9). 1704–1712. 76 indexed citations
10.
Li, Chiang‐Shan R., et al.. (2004). A Psychophysical Measure of Attention Deficit in Children With Attention-Deficit/Hyperactivity Disorder.. Journal of Abnormal Psychology. 113(2). 228–236. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shana White Breakdown of academic impact, for papers by George Kyriakopoulos Breakdown of academic impact, for papers by F. Chapel Breakdown of academic impact, for papers by Lina Jiang Breakdown of academic impact, for papers by Kana Kurokawa Breakdown of academic impact, for papers by Soichiro Kawata Breakdown of academic impact, for papers by David A. Klibansky Breakdown of academic impact, for papers by Qiaofeng Zhong
Rankless by CCL
2026